
GMAB Stock Forecast & Price Target
GMAB Analyst Ratings
Bulls say
Genmab's recent financial performance indicates a strong outlook, highlighted by an operating income that exceeded expectations by 20% while revenues met the market's predictions. With an impressive lineup of near-term clinical catalysts expected over the next 12-18 months, notably in their expanding pipeline, Genmab is poised to enhance product revenue forecasts and strengthen its market position. Furthermore, the company's robust balance sheet, ending Q3 2025 with approximately $3.4 billion in cash and equivalents, positions it favorably to navigate challenges in the biotech sector and supports ongoing growth initiatives.
Bears say
Genmab faces multiple risks that contribute to a negative outlook, particularly the slowing sales of its leading product, Darzalex, which may impact revenue stability. Furthermore, the company is experiencing challenges with key pipeline candidates, including the discontinuation of GEN1042 and the potential competitive threats from emerging therapies, which could hinder future growth opportunities. Additionally, there are overarching concerns such as clinical or regulatory failures of pipeline products and macroeconomic factors that may further exacerbate financial performance uncertainties.
This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.
GMAB Analyst Forecast & Price Prediction
Start investing in GMAB
Order type
Buy in
Order amount
Est. shares
0 shares